- Monday, 17 December 2012
- BRILINTA (ticagrelor) receives additional Class I recommendation in updated ACCF/AHA guidelines for the management of STEMI patients AstraZeneca announced today that a combined panel of experts from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) have updated their guidelines to include a Class I recommendation for use of the oral antiplatelet (OAP) medicine BRILINTA® (ticagrelor) tablets in patients with ST-elevation myocardial infarction (STEMI) managed invasively.
- Friday, 14 December 2012
- CRESTOR® US patent upheld by Court of Appeals for the Federal Circuit AstraZeneca announced today that the Court of Appeals for the Federal Circuit has upheld the decision of the District Court, District of Delaware, finding that the substance patent protecting CRESTOR (rosuvastatin calcium) (RE37,314 – the ‘314 patent) is valid and enforceable.
- Wednesday, 5 December 2012
- AstraZeneca updates US label for FASLODEX® (fulvestrant) injection AstraZeneca today announced agreement with the US Food and Drug Administration (FDA) on label changes for FASLODEX® (fulvestrant) Injection.
- Wednesday, 5 December 2012
- Final overall survival analysis of CONFIRM shows a 4.1 month difference in median overall survival when using FASLODEX® (fulvestrant) injection 500 mg compared with 250 mg. (1,2) Today, updated overall survival (OS) data for FASLODEX® (fulvestrant) Injection in patients with hormone receptor-positive advanced breast cancer whose disease progressed or recurred following prior endocrine therapy was presented at the 35th CTRC-AACR San Antonio Breast Cancer Symposium.
- Tuesday, 4 December 2012
- AstraZeneca to present key new data for hormone receptor-positive metastatic breast cancer at the 35th CTRC-AACR Annual San Antonio Breast Cancer Symposium AstraZeneca today announced the presentation of important new data from studies of FASLODEX® (fulvestrant) Injection at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium taking place from 4-8 December at the Henry B. Gonzalez Convention Center, San Antonio, Texas.
- Tuesday, 4 December 2012
- AstraZeneca makes major commitment to help patients with acute coronary syndrome have BRILINTA (ticagrelor) available in their local communities AstraZeneca today announced a new program with more than 26,000 national, regional and independent pharmacies to broaden stocking of BRILINTA® (ticagrelor) tablets, greatly enhancing its retail availability in the United States.
- Thursday, 15 November 2012
- AZ&Me™ Prescription Savings Program for people with Medicare Part D removes out-of-pocket spend requirement AstraZeneca today announced that it is simplifying the enrollment process for the AZ&Me™ Prescription Savings Program for people with Medicare Part D by removing an out-of-pocket spend requirement.
- Monday, 12 November 2012
- AstraZeneca launches new digital resources for ARIMIDEX® (anastrozole) tablets to help educate patients about ARIMIDEX Direct AstraZeneca (NYSE: AZN) today launched new digital resources to educate patients on how to enroll in ARIMIDEX Direct. Resources include a “how to” video outlining the enrollment process for ARIMIDEX Direct and a digital badge that can be shared via social media platforms and symbolizes support for the program.
- Wednesday, 7 November 2012
- New PLATO analysis evaluates the influence of high-sensitivity troponin biomarker status in NSTE-ACS patients managed with revascularization or medical management AstraZeneca today announced results from a post-hoc analysis of a sub-group of the PLATO study.
- Monday, 29 October 2012
- AstraZeneca begins a new global study of FASLODEX® (fulvestrant) injection in patients with hormone receptor-positive advanced breast cancer AstraZeneca today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy.
Stay in touch
Please note
These press releases were issued in the United States (US) and are posted here as reference information for US investors and journalists only. The information contained in each press release was accurate at the time of issuance, and AstraZeneca assumes no responsibility for updating the information to reflect subsequent developments.
View information on AstraZeneca products, including their current US Prescribing Information.